Tenacia Biopharmaceuticals

Tenacia Biopharmaceuticals is a Shanghai-based clinical-stage biotechnology company dedicated to developing innovative treatments for central nervous system (CNS) disorders. Established in 2021 by a team of industry veterans from global pharmaceutical leaders such as Biogen and Novartis, the firm focuses on the Greater China market through a combination of strategic licensing and internal development. Tenacia's lead assets include KarXT, a first-in-class muscarinic antipsychotic for schizophrenia licensed from Karuna Therapeutics, and troriluzole, a glutamate modulator for spinocerebellar ataxia licensed from Biohaven. The company is actively conducting late-stage clinical trials to address significant unmet medical needs in neurology and psychiatry. Backed by top-tier investors like Sequoia China and Temasek, Tenacia aims to bridge the gap between global CNS innovations and patients in China.